Kezar Life Sciences, Inc. (KZR)

Overview

Kezar Life Sciences, Inc. is a clinical-stage biotechnology firm actively engaged in the innovation and development of small molecule therapeutics. Founded in 2015 and located in South San Francisco, California, the company focuses its research on addressing the unmet medical needs of patients suffering from immune-mediated diseases and cancer. By harnessing its expertise in novel therapeutic development, Kezar Life Sciences aims to improve the quality of life for patients across the United States through groundbreaking medical advancements.

Products and Services

• Zetomipzomib (KZR-616)

  As the flagship product candidate of Kezar Life Sciences, Zetomipzomib represents a revolutionary approach in treating autoimmune diseases. This selective immunoproteasome inhibitor is undergoing rigorous clinical trials across various stages and indications. For patients battling lupus nephritis, dermatomyositis, and polymyositis, Zetomipzomib is in Phase 2b clinical trials. Additionally, it is in Phase 1b clinical trials for those suffering from systemic lupus erythematosus and has successfully completed Phase 2a clinical trials for lupus nephritis. This targeted treatment aims to offer a new beacon of hope for individuals facing these challenging conditions.

• KZR-261

  Kezar Life Sciences’ preclinical developments include KZR-261, a pioneering product that positions itself as a first-in-class protein secretion inhibitor. This novel compound is designed to combat tumors that have developed resistance to conventional chemotherapy treatments. By targeting the protein secretion pathways crucial for tumor growth and survival, KZR-261 has the potential to redefine cancer treatment paradigms and offer new hope to patients with hard-to-treat cancers.